An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

这些问题使得寻找一种更有效、更便捷的治疗方法迫在眉睫。 在此背景下，基于广泛中和抗体（bnAbs）的基因疗法崭露头角。大量研究表明，被动输注强效 bnAbs 能有效抵御免疫缺陷病毒感染，并抑制病毒在人类和非人灵长类动物体内复制。同时，bnAbs 还可借助 Fc ...

近日，一篇发表在国际杂志The Journal of Immunology上题为“Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4 + T ...

Introduction: A limited subset of HIV-1 infected adult individuals typically after at least 2-3 years of chronic infection, develop broadly neutralizing antibodies (bnAbs), suggesting that highly ...

Bars: mean ± SD. The major in vivo readout of this study is autologous neutralization of a highly resistant SIV, differing from HIV-specific broadly neutralizing antibodies (bNAbs). Importantly, ...

Germline precursors and intermediates of broadly neutralizing antibodies (bNAbs) are essential to the understanding of humoral response to HIV-1 infection and B-cell lineage vaccine design. Using a ...